trending Market Intelligence /marketintelligence/en/news-insights/trending/ejdtxmkg4vkiobipbx4v_q2 content esgSubNav
In This List

Indivior secures court order to block Dr. Reddy's launch of Suboxone generic

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond


Indivior secures court order to block Dr. Reddy's launch of Suboxone generic

Indivior PLC secured a temporary restraining order from a district court in New Jersey that stops Dr. Reddy's Laboratories Ltd. from selling a generic version of Suboxone Film, Indivior's opioid addiction treatment.

The action comes a day after Dr. Reddy's received the U.S. Food and Drug Administration's approval to sell the generic. The agency granted approvals to Mylan NV unit Mylan Technologies Inc. and Dr. Reddy's unit Dr. Reddy's Laboratories SA to market the drug in multiple strengths.

The restraining order will remain in place pending a hearing on the preliminary injunction motion filed by Indivior. The motion will result in a hearing at the court where Indivior will seek to extend the cessation of launch activities by Dr. Reddy's pending the outcome of recently filed patent litigation against the company.

The U.S. District Court for the District of New Jersey is expected to hold the hearing on the preliminary injunction motion June 28.

Commenting on the matter, Indivior CEO Shaun Thaxter said the company will continue to pursue "all legal avenues against Dr. Reddy's to protect our Suboxone Film patent estate."